Prehospital Ventilator-Associated Pneumonia Prevention Trial

Overview

Traumatic injury in rural America is a significant cause of morbidity and mortality, and the challenges of a rural trauma system can put patients at unique risk. Prolonged transport times to a trauma center, stopping for care at referring hospitals, and longer exposure to care-associated factors distinguish rural patients from their urban counterparts. Ventilator-associated pneumonia (VAP) is a significant risk in rural patients, increasing hospital stay, healthcare costs, and even mortality in the critically injured. The investigators propose a pilot study to test the hypothesis that a single dose of oral chlorhexidine gluconate (antiseptic) for trauma patients in the prehospital environment will decrease subsequent development of early VAP. Chlorhexidine is currently a standard therapy in intensive care units to prevent airway colonization and subsequent development of VAP. Demonstrating safety and effectiveness of prehospital infection control practices could significantly improve outcomes of traumatic injury in rural America.

Full Title of Study: “A Pilot Study of Prehospital Oral Chlorhexidine Gluconate to Prevent Early Ventilator Associated Pneumonia in Intubated Trauma Patients”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: October 2014

Interventions

  • Drug: Chlorhexidine gluconate
    • Study solution will be applied to the oropharynx and will be distributed for 15 seconds with a swab stick. No suction will be applied for at least 30 seconds.

Arms, Groups and Cohorts

  • Chlorhexidine gluconate
    • Intubated subjects transported by one air service will be treated with 5 mL chlorhexidine gluconate 0.12% applied for at least 30 seconds during helicopter transport.
  • Normal saline (placebo)
    • Intubated subjects assigned transported by another air service will not have any additional treatment (in addition to usual care) during helicopter transport.

Clinical Trial Outcome Measures

Primary Measures

  • Clinical Pulmonary Infection Score (CPIS)
    • Time Frame: 48-72 hours

Secondary Measures

  • Pneumonia – CPIS
    • Time Frame: 5 days
    • This is the diagnosis of pneumonia within the first 5 days defined by CPIS score >=6.
  • Pneumonia – CDC
    • Time Frame: 5 days
    • This is the diagnosis of pneumonia using CDC criteria within 5 days of admission.
  • Pneumonia – Treated
    • Time Frame: 5 days
    • This is the diagnosis of pneumonia defined as antibiotic treatment of suspected pneumonia by the treating clinician.
  • Pneumonia – Research
    • Time Frame: 5 days
    • This is the diagnosis of pneumonia within 5 days as adjudicated by 3 clinicians blinded to treatment allocation.
  • 28-day ventilator-free days
    • Time Frame: 28 days
  • 28-day ICU-free days
    • Time Frame: 28 days
  • Hospital Mortality
    • Time Frame: 28-days
  • Tracheostomy Rate
    • Time Frame: 28 days
  • Tracheal colonization
    • Time Frame: 48-72 hours
    • This analysis will be completed in two ways: the raw analysis will use a chi-squared test to test the null hypothesis that the distribution of semi-quantitative tracheal colonization is the same in the two groups. A second analysis will be performed using the ordinal shift method to compare the change (shift) in the semiquantitative score between admission and 48-72 hours.

Participating in This Clinical Trial

Inclusion Criteria

  • Adults (age >= 18 years) – Endotracheal intubation – Transported by air ambulance – Traumatic injury – Interfacility transport (no flights from scene) en route to University of Iowa Hospitals and Clinics) Exclusion Criteria:

  • Known or suspected pregnancy – Prisoners – Patients diagnosed with pneumonia prior to transfer – Known allergy to chlorhexidine gluconate – Surgical airway (tracheostomy or cricothyroidotomy) – Massive aspiration – Anticipated nonsurvivable injury (survival projected < 24 hours)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Nicholas M Mohr
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Nicholas M Mohr, Assistant Professor of Emergency Medicine and Anesthesia Critical Care – University of Iowa
  • Overall Official(s)
    • Nicholas M Mohr, MD, Principal Investigator, University of Iowa

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.